Kesbury
Sermorelin · Basics

What is sermorelin?

A growth hormone-releasing hormone analog that signals your own pituitary rather than replacing the hormone. What it is, what it is not, and what the published evidence actually shows.

Medically reviewed by the Kesbury Health Clinical Team · Last updated 2026-09-02

Quick answer

Sermorelin is a growth hormone-releasing hormone (GHRH) analog: a compounded peptide that signals the pituitary gland to produce and release the body's own growth hormone, rather than introducing synthetic growth hormone directly. It is a prescription medication, dispensed by a licensed U.S. compounding pharmacy after a physician evaluation, and self-administered at home as a small subcutaneous injection. Sermorelin is the active ingredient of a previously approved drug (Geref, withdrawn from the market in 2008 for commercial reasons rather than for safety or effectiveness), which is the basis for physician-directed 503A compounding today. Compounded sermorelin is not an FDA-approved finished drug product. It may support sleep quality, recovery and body composition goals associated with healthy growth hormone signaling, and individual results vary.

What does sermorelin actually do in the body?

Growth hormone is not released in a steady trickle. The pituitary gland puts it out in pulses, and those pulses are triggered by a signal from the hypothalamus called growth hormone-releasing hormone. Sermorelin is a synthetic version of the first 29 amino acids of that signal, the fragment that carries the biological activity.

The practical consequence is where the medication sits in the chain. Injected growth hormone bypasses the body's own control loop. A GHRH analog works through it: the pituitary still decides how much to release, and the negative feedback that normally shuts the pulse down still operates. That is a mechanistic difference, not a claim that one is better for you than the other.

Why is sermorelin discussed in the context of aging?

Because the signal itself weakens with age, and that has been measured. In a 1991 study of healthy men, researchers reported that each decade of increasing age attenuated the growth hormone production rate by 14% and the half-life of circulating growth hormone by 6% [4]. Older men in a 1992 controlled study had lower growth hormone and insulin-like growth factor 1 (IGF-1) levels than young men, and twice-daily GHRH(1-29) injections over 14 days reversed that difference [1].

So the interest is a reasonable hypothesis with a real physiological basis. It is not the same thing as a demonstrated benefit for how you feel day to day, and it should not be read as one.

How is sermorelin different from growth hormone therapy?

  • Where it acts. Growth hormone therapy supplies the hormone. Sermorelin supplies the upstream signal and lets the pituitary respond [3].
  • Regulatory status. Recombinant human growth hormone is an approved drug with narrow approved indications. Compounded sermorelin is not an FDA-approved finished product; it is compounded under 503A rules.
  • What the evidence base looks like. Growth hormone in healthy older adults has been studied in a systematic review, which concluded that adverse events were more common in the growth hormone groups than in controls [5]. Sermorelin's own controlled data in older adults is smaller and older [1][2].

An honest summary is that the two are related but not interchangeable, and that neither is a longevity treatment in any established sense.

Who typically looks into sermorelin?

Adults who want a physician-directed evaluation before starting a peptide therapy, rather than a questionnaire-only online purchase. Often the stated goals are sleep quality, recovery from training, and body composition. Those are goals, not promises, and the honest framing is that sermorelin may support them within a supervised plan while individual results vary.

What sermorelin is not

  • It is not an FDA-approved finished drug product.
  • It is not a treatment for any disease, and it is not a substitute for a workup when a symptom has a cause worth finding.
  • It is not something to source without a prescription. Compounded medication from an unlicensed source is a different product with a different risk profile.
  • It is not appropriate for people with certain histories. That is what the evaluation and the baseline panel are for.

How physician-directed sermorelin works at Kesbury Health

  1. Complete a short online assessment about your goals, symptoms and health history. It takes about 60 seconds to begin.
  2. A licensed Kesbury Health physician reviews what you submitted and decides whether therapy is a reasonable fit for you, or whether something else should be looked at first.
  3. Baseline labs where they apply. The $179 Sermorelin Baseline Panel is a prerequisite for sermorelin therapy, and the results can end the conversation rather than continue it.
  4. If therapy is appropriate, the medication is compounded by a licensed U.S. pharmacy and shipped to your door, with dosing set to you rather than to a chart.
  5. Ongoing physician oversight adjusts the protocol over time, with a 90-day re-evaluation built into the sermorelin program.

Care is delivered by telehealth to residents of the ten states where your Kesbury Health physician is licensed: Alabama, District of Columbia, Delaware, Florida, Maryland, Michigan, New Jersey, Ohio, Pennsylvania and Texas. Eligibility is confirmed during the assessment.

Frequently asked questions

Is sermorelin legal to prescribe?

Sermorelin is the active ingredient of a previously approved drug, Geref, which supports its basis for compounding under FDA 503A rules when a licensed physician prescribes it for an individual patient and a licensed 503A pharmacy fills it. Compounded sermorelin is not itself an FDA-approved finished drug product, and Kesbury Health states that distinction plainly rather than implying broader approval.

Is sermorelin the same thing as HGH?

No. Human growth hormone therapy introduces synthetic growth hormone into the body. Sermorelin acts one step upstream: it is a growth hormone-releasing hormone analog that signals the pituitary gland to release the body's own growth hormone, so the body's own feedback controls still apply. The two are different medications with different regulatory status and different monitoring.

Do you need labs before starting sermorelin?

At Kesbury Health, yes. The $179 Sermorelin Baseline Panel is a prerequisite for sermorelin therapy, not an optional add-on. It gives the prescribing physician a reference point for individualized dosing, and results that argue against therapy mean therapy is not prescribed.

How long has sermorelin been studied?

Sermorelin has a research record going back to the 1980s. Controlled studies in older adults were published in the early 1990s [1][2], and it was reviewed as a pediatric growth hormone deficiency therapy in 1999 [3]. That history is one reason its compounding basis differs from newer peptides that circulate online without it.

Is sermorelin FDA-approved as a finished product today?

No. Compounded sermorelin is not an FDA-approved finished drug product. It is compounded under 503A rules on the basis of its status as the active ingredient of a previously approved drug. That is a meaningfully different legal category from an FDA-approved medication.

See whether sermorelin fits your goals

Take the free 60-second Kesbury Health assessment. A licensed physician reviews your goals and health history, the baseline panel establishes whether sermorelin is a reasonable fit, and if it is, your physician-directed plan ships to your door.

Start your free 60-second assessment →

Kesbury Health is a LegitScript-certified (#51875982) telehealth longevity practice licensed in ten states. Sermorelin and NAD+ are compounded medications prescribed by a licensed physician after review. Compounded medications are not FDA-approved. This page is educational and is not individualized medical advice. Statements on this page have not been evaluated by the FDA. Individual results vary.

References (primary sources)

Every reference below was checked against its PubMed record on 2026-09-02. Links open the abstract.

  1. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. 1992;75(2):530-535. doi:10.1210/jcem.75.2.1379256. PMID 1379256.
  2. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. doi:10.1016/s0026-0495(97)90174-8. PMID 9005976.
  3. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007. PMID 18031173.
  4. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology and Metabolism. 1991;73(5):1081-1088. doi:10.1210/jcem-73-5-1081. PMID 1939523.
  5. Liu H, Bravata DM, Olkin I, Nayak S, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. 2007;146(2):104-115. doi:10.7326/0003-4819-146-2-200701160-00005. PMID 17227934.

Keep reading